Profitability
Here’s a comparison of Spectral AI’s performance against its competitors:
| Net Margins | Return on Equity | Return on Assets | |
| Spectral AI | -89.85% | N/A | -104.64% |
| Competitors | -578.37% | -140.27% | -25.88% |
Ownership
67.1% of Spectral AI shares are owned by institutions, higher than the 47.4% average for the “Surgical & Medical Instruments” sector. Additionally, 56.7% of shares are held by company insiders compared to 15.9% for the sector. This indicates strong confidence in Spectral AI’s growth potential.
Volatility
Spectral AI’s beta is 0.56, making it less volatile than the S&P 500. Its competitors have a beta of 0.53, also indicating lower volatility.
Analyst Ratings
Recent ratings for Spectral AI are as follows:
| Sell | Hold | Buy | Strong Buy | Rating Score | |
| Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
| Competitors | 1663 | 4406 | 8446 | 251 | 2.49 |
The consensus target price for Spectral AI is $4.50, indicating a potential 265.85% increase, compared to 17.84% for its sector.
Valuation
Comparison of revenue and profitability:
| Gross Revenue | Net Income | P/E Ratio | |
| Spectral AI | $18.06 million | -$20.85 million | -0.92 |
| Competitors | $870.57 million | $47.37 million | -1.16 |
Competitors have higher revenues and profits. Spectral AI’s P/E ratio indicates it’s currently more expensive than its peers.
Summary
Spectral AI performs better than its peers in 10 out of 13 categories.
Company Profile
Spectral AI, Inc. is focused on developing AI-based medical diagnostics for better treatment decisions in wound care. Its products include the DeepView System and DeepView SnapShot M, which assist in assessing wound healing potential and are useful for emergency care professionals. The company is based in Dallas, Texas.
Receive Daily News & Ratings for Spectral AI – Enter your email for a summary of the latest news and analyst ratings for Spectral AI and related companies with MarketBeat.com’s FREE daily email newsletter.
`
